bioAffinity Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIAF research report →
Price Chart
About the company
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer.
- CEO
- Maria Zannes
- IPO
- 2022
- Employees
- 57
- HQ
- San Antonio, TX, US
Get TickerSpark's AI analysis on BIAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.54M
- P/E
- -0.05
- PEG
- -0.00
- P/S
- 0.43
- P/B
- 0.56
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- -39.57%
- Op Margin
- -209.82%
- Net Margin
- -257.33%
- ROE
- -257.27%
- ROIC
- -237.93%
Latest fiscal year · YoY change
- Revenue
- $6.16M-34.2%
- Gross Profit
- $1.43M-57.7%
- Op Income
- $-10,572,508
- Net Income
- $-14,909,754-64.9%
- EPS
- $-129.90+61.5%
- OCF Growth
- -28.4%
- FCF Growth
- -27.9%
- 52W High
- $80.70
- 52W Low
- $4.56
- 50D MA
- $7.63
- 200D MA
- $20.66
- Beta
- -1.11
- RSI (14)
- 43
- Avg Volume
- 3.17M
No earnings-call transcripts are available for BIAF yet.
- Free Float
- 70.4%
- Shares Outstanding
- 1.17M
- Float Shares
- 294.80K
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sabby Management, LLC | 365.65K | ▲ 365.65K |
| Blackrock, Inc. | 98.78K | ▲ 98.78K |
| Vanguard Capital Management LLC | 55.54K | 0 |
| Geode Capital Management, LLC | 50.97K | ▲ 2.67K |
| J. Safra Sarasin Holding AG | 42.60K | 0 |
| Vanguard Fiduciary Trust Co | 31.07K | 0 |
| Susquehanna International Group, Llp | 26.87K | ▲ 26.87K |
| Jane Street Group, LLC | 26.78K | ▲ 26.78K |
| State Street Corp | 24.09K | ▲ 9.70K |
| Hrt Financial LP | 20.83K | ▲ 20.83K |
| Northern Trust Corp | 16.75K | ▲ 4.02K |
| Virtu Financial LLC | 11.11K | ▲ 11.11K |
Held by 7 ETFs
Biggest fund positions in BIAF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 12, 25 | Rios Roberto | other | 0 |
| Aug 12, 25 | Oppenheimer John J. | other | 0 |
| Jan 10, 25 | Reveles Xavier Trinidad | other | 21,604 |
| Jan 10, 25 | GIRGENTI STEVEN | other | 14,814 |
| Jan 10, 25 | Zannes Maria | other | 37,037 |
| Jan 10, 25 | Edwards James Michael | other | 6,172 |
| Jan 10, 25 | Zannes Timothy P | other | 8,641 |
| Nov 5, 24 | Edwards James Michael | other | 100,000 |
| Sep 16, 24 | Edwards James Michael | other | 0 |
| Sep 1, 22 | Edwards James Michael | other | 5,876 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIAF coverage
Recent articles, reports, and earnings notes.
No research on BIAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIAF report →bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
businesswire.com · Oct 6
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
businesswire.com · Sep 30
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
businesswire.com · Sep 22
BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant
benzinga.com · Sep 17
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
businesswire.com · Sep 17
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
businesswire.com · Sep 9
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
businesswire.com · Sep 3
BioAffinity Technologies Stock Skyrockets Wednesday: What's Happening?
benzinga.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.